The phrase "a significant subgroup of" is correct and usable in written English.
It can be used when referring to a notable or important portion of a larger group, often in discussions related to demographics, research, or social studies.
Example: "In the study, a significant subgroup of participants reported experiencing anxiety during the pandemic."
Alternatives: "an important subset of" or "a notable segment of".
But mention should be made of a significant subgroup of this population with special needs: the mentally ill.
This research is expected to produce a strategy for pharmacological treatment of OSA in a significant subgroup of patients who cannot tolerate the current treatment options.
A significant subgroup of metastatic renal cell carcinoma (mRCC) patients discontinue vascular endothelial growth factor-targeted therapies (VEGF-TT) because of toxicity.
These primers can specifically identify the genus as a whole, only Dekkera species, each one of the five recognised species as well as a significant subgroup of D. bruxellensis represented by NCYC 3426.
Moreover, it's not working for a significant subgroup of Americans in Afghanistan either: combat soldiers.
Nevertheless, a significant subgroup of patients develops tumour recurrence.
In conclusion, these data demonstrate that a significant subgroup (approximately one-quarter) of MSS CRCs exist with elevated mutation rates that are likely independent of one another.
The effect size did not vary according to study quality, but a significant subgroup analysis on timing of the pregnancy test, a contour enhanced funnel plot, and Egger's test indicated the presence of moderate publication bias.
Bleeding patients are therefore a clinically significant subgroup of the trauma population and have been the focus of recent research on trauma physiology, haemostatic agents, near-patient coagulation testing, damage control resuscitation, and consolidating best-practice management [ 1– 8].
This is the first study to demonstrate the existence of a clinically significant subgroup of patients with HER-2-positive early breast cancer, who experience a favourable long-term outcome that can be identified with a validated and commercially available gene expression assay.
They are the classical protagonists of the expanding group of myofibrillar myopathies (MFMs), a numerically significant subgroup of hereditary and sporadic protein aggregate myopathies with marked clinical and genetic heterogeneity due to mutations of the desmin, αB-crystallin, BAG-3, FHL1, filamin-C, myotilin, plectin, and ZASP genes [ 37].
